The US Federal Drug Administration (FDA) approved Eli Lilly (LLY) new GLP-1 weight-loss pill. Eli Lilly also struck a deal ...
Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.
1d
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult ...
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...
GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk’s (NYSE:NVO) ...
Eli Lilly is much more than just a weight loss stock.
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.
A catalyst for stock performance may be just ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results